Clinical Trial Update: The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression [Phase 3]

View source ↗

Summary

This update notes the completion of a Phase 3 study evaluating the fixed-dose combination of olanzapine and fluoxetine for treatment-resistant depression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• olanzapine/fluoxetine fixed-dose combination (olanzapine/fluoxetine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED